{"Clinical Trial ID": "NCT00243503", "Intervention": ["INTERVENTION 1:", "Trastuzumab + Sunitinib", "Trastuzumab was administered intravenously (i.v.) weekly (loading 4 mg/kg followed by 2 mg/kg per week) or every 3 weeks (loading 8 mg/kg followed by 6 mg/kg three times per week)."], "Eligibility": ["Incorporation criteria:", "A diagnosis of breast cancer with signs of 1) non-resectable, locally recurrent disease, or 2) metastatic.", "HER2 positive disease (3+ by immunohistochemistry [IHC] or FISH-positive)", "Prior treatment with trastuzumab and/ or lapatinib is permitted for neoadjuvant, adjuvant or metastatic diseases. Hormonotherapy for adjuvant and/or advanced diseases is permitted.", "- Exclusion criteria:", "Prior treatment with > 1 cytotoxic treatment for advanced disease is allowed. Adjuvant chemotherapy is allowed.", "A prior exposure to trastuzumab if the patient had developed severe hypersensitivity reactions.", "Prior treatment in a clinical trial SU11248.", "Uncontrolled brain metastases."], "Results": ["Performance measures:", "Percentage of participants with a confirmed overall response to the disease", "A CR was defined as the disappearance of all target and non-target lesions. A PR was defined as a decrease > = 30% of the sum of the longest dimensions of the target lesions by taking as reference the sum of the longest dimensions associated with a non-target response to non-target lesions.", "Duration: From start of treatment to 18 months", "Results 1:", "Title of arm/group: Trastuzumab + Sunitinib", "Description of the arm/group: Trastuzumab was administered intravenously (i.v.) weekly (loading 4 mg/kg followed by 2 mg/kg per week) or every 3 weeks (loading 8 mg/kg followed by 6 mg/kg three times per week).", "Total number of participants analysed: 57", "Type of measurement: Number", "Unit of measure: percentage of participants 36.8 (24.4-50.7)"], "Adverse Events": ["Undesirable Events 1:", "Total: 25/60 (41.67%)", "Anemia * 1/60 (1.67%)", "Febrile neutropenia * 2/60 (3.33%)", "idiopathic thrombocytopenic purpura * 1/60 (1.67%)", "Thrombocytopenia * 3/60 (5.0%)", "* 1/60 (1.67%)", "Acute heart failure * 1/60 (1.67%)", "Cardiogenic shock * 1/60 (1.67%)", "Left ventricular dysfunction * 1/60 (1.67%)", "Anal fistula * 1/60 (1.67%)"]}